今日の臨床サポート

膵神経内分泌腫瘍(p-NET)

関連論文:
img  6:  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).
 
著者: John K Ramage, A Ahmed, J Ardill, N Bax, D J Breen, M E Caplin, P Corrie, J Davar, A H Davies, V Lewington, T Meyer, J Newell-Price, G Poston, N Reed, A Rockall, W Steward, R V Thakker, C Toubanakis, J Valle, C Verbeke, A B Grossman, UK and Ireland Neuroendocrine Tumour Society
雑誌名: Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.
Abstract/Text These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology, the Society for Endocrinology, the Association of Surgeons of Great Britain and Ireland (and its Surgical Specialty Associations), the British Society of Gastrointestinal and Abdominal Radiology and others. The authorship represents leaders of the various groups in the UK and Ireland Neuroendocrine Tumour Society, but a large amount of work has been carried out by other specialists, many of whom attended a guidelines conference in May 2009. We have attempted to represent this work in the acknowledgements section. Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments. However, there remain few randomised trials in the field and the disease is uncommon, hence all evidence must be considered weak in comparison with other more common cancers.

PMID 22052063  Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから